Page 26 - August 2022_Fulldraftforflipbook_revised

Elterman et al

81. Ruszat R, Wyler S, Forster T et al. Safety and effectiveness of photoselective vaporization on of the prostate 100. Carnevale FC, Iscaife A, Yoshinaga EM, et al. Transurethral resection of the prostate (TURP) vs. original and
(PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007;51:1031. https://doi.org/10.1016/j. PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (bph): Preliminary results
eururo.2006.08.006 of a single-center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 2016;39:44-52.
82. Bowen JM, Whelan JP, Hopkins RB, et al. Photoselective vaporization for the treatment of benign prostatic https://doi.org/10.1007/s00270-015-1202-4
hyperplasia. Ont Health Technol Assess Ser 2013;13:1-34. 101. Gao YA, Huang Y, Zhang R, et al. Benign prostatic hyperplasia: Prostatic arterial embolization vs. trans-
83. Lourenco T, Shaw M, Fraser C, et al. The clinical effectiveness of transurethral incision of the urethral resection of the prostate — a prospective, randomized, and controlled clinical trial. Radiology
prostate: A systematic review of randomized controlled trials. World J Urol 2010;28:23-32. 2014;270:920-8. https://doi.org/10.1148/radiol.13122803
https://doi.org/10.1007/s00345-009-0496-8 102. Shim SR, Kanhai KJ, Ko YM, et al. Efficacy and safety of prostatic arterial embolization: Systematic
84. de la Rosette J, Laguna MP, Gravas S, et al. Transurethral microwave thermotherapy: The gold standard for review with meta-analysis and meta-regression. J Urol 2017;197:465-79. https://doi.org/10.1016/j.
minimally invasive therapies for patients with benign prostatic hyperplasia? J Endourol 2003;17:245-51. juro.2016.08.100
https://doi.org/10.1089/089277903765444393 103. Russo GI, Kurbatov D, Sansalone S, et al. Prostatic arterial embolization vs. open prostatectomy: A
85. D’Ancona FC, van der Bij AK, Francisca EA, et al. Results of high-energy transurethral microwave ther- one-year matched-pair analysis of functional outcomes and morbidities. Urology 2015;86:343-8.
motherapy in patients categorized according to the American Society of Anesthesiologists operative risk https://doi.org/10.1016/j.urology.2015.04.037
classification. Urology 1999;53:322-8. https://doi.org/10.1016/S0090-4295(98)00502-0 104. Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) vs.
86. Gravas S, Laguna P, Kiemenen LA, et al. Durability of 30-minute high-energy transurethral microwave transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomized, open label,
therapy for treatment of benign prostatic hyperplasia: A study of 213 patients with and without urinary non-inferiority trial. BMJ 2018;361:k2338. https://doi.org/10.1136/bmj.k2338
retention. Urology 2007;69:854-8. https://doi.org/10.1016/j.urology.2007.01.070 105. Bhatia S, Sinha VK, Harward S, et al. Prostate artery embolization in patients with prostate volumes
87. Vanderbrink BA, Rastinehad AR, Badlani G. Prostatic stents for the treatment of benign prostatic hyperplasia. of 80 ml or more: A single-institution retrospective experience of 93 patients. J Vasc Interv Radiol
Curr Opin Urol 2007;17:1-6. https://doi.org/10.1097/MOU.0b013e3280117747 2018;29:1392-8. https://doi.org/10.1016/j.jvir.2018.05.012
88. Senksen J, Barber NJ, Speakman, MJ et al. Prospective, randomized, multinational study of prostatic 106. Kably I, Acharya V, Richardson AJ, et al. Prostatic artery embolization in refractory hematuria of prostatic
urethral lift vs. transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol origin. Tech Vasc Interv Radiol 2020;23:100694. https://doi.org/10.1016/j.tvir.2020.100694
2015;68:643-52. https://doi.org/10.1016/j.eururo.2015.04.024 107. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary reten-
89. Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective, randomized controlled tion from benign prostatic hyperplasia. BJU Int 2005;95:354-7. https://doi.org/10.1111/j.1464-
prostatic urethral L.I.F.T. study. Can J Urol 2017;24:8802-13. 410X.2005.05299.x
90. Rukstalis D, Grier D, Stroup SP, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month 108. McNeill SA, Hargreave TB, Roehrborn CG. Alfaur study group. Alfuzosin 10 mg once daily in the manage-
results of the MedLift Study. Prostate Cancer Prostatic Dis 2019;22:411-9. https://doi.org/10.1038/ ment of acute urinary retention: Results of a double-blind, placebo-controlled study. Urology 2005;65:83-9.
s41391-018-0118-x https://doi.org/10.1016/j.urology.2004.07.042
91. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy 109. Patel SB, Ranka K, Kundargi VS, et al. Comparison of tamsulosin and silodosin in the management of acute
ablation: A multicenter, randomized controlled study for the treatment of lower urinary tract symptoms urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter:
secondary to benign prostatic hyperplasia. J Urol 2016;195:1529-38. https://doi.org/10.1016/j. A prospective, randomized study. Cent European J Urol 2017;70:259-63. https://doi.org/10.5173/
juro.2015.10.181 ceju.2017.1313
92. McVary KT, Gange SN, Gittelman MC, et al. Erectile and ejaculatory function preserved with convective 110. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function:
water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyper- Report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn
plasia: Randomized controlled study. J Sex Med 2016;13:924-33. https://doi.org/10.1016/j. 2002;21:167-78. https://doi.org/10.1002/nau.10052
jsxm.2016.03.372 111. Chapple CR, Osman NI, Birder L, et al. The underactive bladder: A new clinical concept? Eur Urol
93. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter, random- 2015;68:351-3. https://doi.org/10.1016/j.eururo.2015.02.030
ized, sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe 112. Potts B, Belsante M, Peterson A, et al. Bladder outlet procedures are an effective treatment for patients with
lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2021;206:715-24. urodynamically confirmed detrusor underactivity without bladder outlet obstruction. J Urol 2016;195:e975.
https://doi.org/10.1097/JU.0000000000001778 https://doi.org/10.1016/j.juro.2016.02.1712
94. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 113. Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients
One-year results. J Urol 2017;197:1565-72. https://doi.org/10.1016/j.juro.2017.01.056 with detrusor underactivity or acontractility. Urology 2016;97:208-11. https://doi.org/10.1016/j.
95. Gilling P, Barner N, Bidair M, et al. WATER: A double-blind, randomized controlled trial of aquablation urology.2016.07.010
vs. transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2018;199:1252-61. 114. Delakas D, Lianos E, Karyotis I, et al. Finasteride: A long-term followup in the treatment of
https://doi.org/10.1016/j.juro.2017.12.065 recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001;67:69-72.
96. Amparore D, Fiori C, Valerio M, et al. 3-year results following treatment with the second generation of the https://doi.org/10.1159/000050948
temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate 115. Thompson IN, Goodman PJ, Tangen CM, et al. The influence of finasteride in the development of prostate
Cancer Prostatic Dis 2021;24:349-57. https://doi.org/10.1038/s41391-020-00281-5 cancer. N Engl J Med 2003;349:211-20. https://doi.org/10.1056/NEJMoa030660
97. Chughtai B, Elterman D, Shore N, et al. The iTind temporarily implanted nitinol device for the treatment 116. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl
of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A multicenter, randomized, J Med 2010;362:1192-202. https://doi.org/10.1056/NEJMoa0908127
controlled trial. Urology 2020;153:270-6. https://doi.org/10.1016/j.urology.2020.12.022 117. Grubb RL, Andriole G, Sommerville MC, et al. The REDUCE followup study: Low rate of new prostate cancer
98. De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary diagnosis observed during a two-year, observational followup study of men who participated in the REDUCE
implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World trial. J Urol 2013;189:871-977. https://doi.org/10.1016/j.juro.2012.09.099
J Urol 2021;39:2037-42. https://doi.org/10.1007/s00345-020-03418-2 118. Klotz L, Chetner M, Chin J, et al. Canadian consensus conference: The FDA decision on the use of 5ARIs.
99. Pisco JM, Rio Tinto H, et al. Embolization of prostatic arteries as treatment of moderate to severe lower Can Urol Assoc J 2012;6:83-8. https://doi.org/10.5489/cuaj.12058
urinary symptoms (LUTS) secondary to benign hyperplasia: Results of short- and mid-term followup. Eur
Radiol 2013;23:2561-72. https://doi.org/10.1007/s00330-012-2714-9 Correspondence: Dr. Dean Elterman, Division of Urology, University of Toronto, Toronto, ON, Canada;
Dean.Elterman@uhn.ca

256 CUAJ • August 2022 • Volume 16, Issue 8